mProX™ Human CD47 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD47 is a cell surface receptor that plays multiple inhibitory roles in various biological processes. In the context of myelin debris clearance in peripheral nerve and spinal cord injuries (PNI) and multiple sclerosis (MS), CD47 on myelin inhibits phagocytosis by binding to SIRPα on macrophages and microglia. Deletion of CD47 accelerates myelin debris clearance, axon regeneration, and functional recovery in PNI. CD47 also inhibits myelin disruption/dismantling and debris scavenging in Schwann cells, as well as myelin debris phagocytosis in macrophages. In the field of cancer immunotherapy, CD47 blockade using an immunotherapy antibody called magrolimab has shown promising results in inhibiting tumor growth, decreasing metastasis, and improving survival in a humanized mouse model of Ewing sarcoma. Additionally, CD47 has been implicated in disrupting the tumor microenvironment and regulating alternative splicing events in myocardial ischemia reperfusion injury. Furthermore, biomimetic nanocarriers loaded with pro-resolving lipid mediators, including CD47, have been developed for the resolution of inflammation in atherosclerosis. Overall, CD47 has diverse applications in various fields, including neuroinflammation, cancer immunotherapy, cardiovascular diseases, and inflammation-related conditions.